EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD

Christopher P Webster iD, Bradley Hall iD, Olivia M Crossley, Dana Dauletalina iD, Marianne King, Ya-Hui Lin iD, Lydia M Castelli, Zih-Liang Yang, Ian Coldicott, Ergita Kyrgiou-Balli iD, Adrian Higginbottom, Laura Ferraiuolo iD und 5 weitere

Life Science Alliance · 2025

DOI: 10.26508/lsa.202402757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, 2025. Verfasst von Christopher P Webster und 16 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Institute for Translational Neuroscience (SITraN), Division of Neuroscience, School of Medicine and Population Health, Faculty of Health, U…. Hauptthemen laut MEDLINE: C9orf72 Protein, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Disease Models, Animal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, European Research Council, Alzheimer’s Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A G4C2 hexanucleotide repeat expansion in C9orf72 is the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD). Bidirectional transcription and subsequent repeat-associated non-AUG (RAN) translation of sense and antisense transcripts leads to the formation of five dipeptide repeat (DPR) proteins. These DPRs are toxic in a wide range of cell and animal models. Therefore, decreasing RAN-DPRs may be of therapeutic benefit in the context of C9ALS/FTD. In this study, we found that C9ALS/FTD patients have reduced expression of the AAA+ family members RuvBL1 and RuvBL2, which have both been implicated in aggregate clearance. We report that overexpression of RuvBL1, but to a greater extent RuvBL2, reduced C9orf72-associated DPRs in a range of in vitro systems including cell lines, primary neurons from the C9-500 transgenic mouse model, and patient-derived iPSC motor neurons. In vivo, we further demonstrated that RuvBL2 overexpression and consequent DPR reduction in our Drosophila model was sufficient to rescue a number of DPR-related motor phenotypes. Thus, modulating RuvBL levels to reduce DPRs may be of therapeutic potential in C9ALS/FTD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C9orf72 ProteinAmyotrophic Lateral SclerosisFrontotemporal DementiaDisease Models, AnimalDipeptidesATPases Associated with Diverse Cellular ActivitiesDNA HelicasesMice, TransgenicAnimalsHumansMiceDNA Repeat ExpansionCarrier ProteinsMotor NeuronsInduced Pluripotent Stem CellsMale

Substanzen

C9orf72 ProteinDipeptidesATPases Associated with Diverse Cellular ActivitiesRUVBL2 protein, humanDNA HelicasesRUVBL1 protein, humanCarrier ProteinsC9orf72 protein, human

Autor:innen und Institutionen

  • Sheffield Institute for Translational Neuroscience (SITraN), Division of Neuroscience, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield, UK c.p.webster@sheffield.ac.uk.
  • Neuroscience Institute, University of Sheffield, Sheffield, UK.
  • Sheffield Institute for Translational Neuroscience (SITraN), Division of Neuroscience, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield, UK.
  • Healthy Lifespan Institute (HELSI), University of Sheffield, Sheffield, UK.
  • Sheffield Institute for Translational Neuroscience (SITraN), Division of Neuroscience, School of Medicine and Population Health, Faculty of Health, University of Sheffield, Sheffield, UK m.azzouz@sheffield.ac.uk.
  • Gene Therapy Innovation and Manufacturing Centre (GTIMC), Division of Neuroscience, University of Sheffield, Sheffield, UK.

ORCID-Profile: Christopher P Webster, Bradley Hall, Dana Dauletalina, Ya-Hui Lin, Ergita Kyrgiou-Balli, Laura Ferraiuolo, Kurt J De Vos, Guillaume M Hautbergue, Pamela J Shaw, Ryan Jh West, Mimoun Azzouz

Förderung

  • Medical Research Council
  • European Research Council
  • Alzheimer’s Research UK
  • Innovative Medicines Initiative 2 Joint Undertaking
  • European Federation of Pharmaceutical Industries and Associations
  • EU Joint Programme – Neurodegenerative Disease Research
  • EC | European Research Council
  • MRC DPFS Award

Zitieren

APA

Webster, C. P., Hall, B., Crossley, O. M., Dauletalina, D., King, M., Lin, Y. H., Castelli, L. M., Yang, Z. L., Coldicott, I., Kyrgiou-Balli, E., Higginbottom, A., Ferraiuolo, L., De Vos, K. J., Hautbergue, G. M., Shaw, P. J., West, R. J., & Azzouz, M. (2025). RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD. Life Science Alliance. https://doi.org/10.26508/lsa.202402757

Vancouver

Webster CP, Hall B, Crossley OM, Dauletalina D, King M, Lin YH, et al. RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD. Life Science Alliance. 2025. doi:10.26508/lsa.202402757

BibTeX
@article{Webster2025,
  author = {Webster, Christopher P and Hall, Bradley and Crossley, Olivia M and Dauletalina, Dana and King, Marianne and Lin, Ya-Hui and Castelli, Lydia M and Yang, Zih-Liang and Coldicott, Ian and Kyrgiou-Balli, Ergita and Higginbottom, Adrian and Ferraiuolo, Laura and De Vos, Kurt J and Hautbergue, Guillaume M and Shaw, Pamela J and West, Ryan Jh and Azzouz, Mimoun},
  title = {RuvBL1/2 reduce toxic dipeptide repeat protein burden in multiple models of C9orf72-ALS/FTD},
  journal = {Life Science Alliance},
  year = {2025},
  doi = {10.26508/lsa.202402757}
}
Kostenlos starten →